Silence Therapeutics plc
SLN59
$3.32arrow_drop_up9.83%$0.30
Penny Stock
SLN59
$3.32
arrow_drop_up9.83%| Key Stats | |
|---|---|
| Open | $3.15 |
| Prev. Close | $3.05 |
| EPS | -1.70 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $132.22M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 3.05 | 3.39 |
| 52 Week Range | 1.97 | 27.72 |
| Ratios | |
|---|---|
| EPS | -1.70 |
| Fundamentals | |
|---|---|
| Payout Ratio | - |
| Industry average yield | 2.87% |
| Last Dividend pay date | - |
| Dividend per share | - |
| Dividend yield forecast | - |
Stock Analysis
Technicals
Summarizing what the indicators are suggesting.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Analyst rating
An aggregate view of professional's ratings.
—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell
Stock Performance
SLN-
US Healthcare Sector-
US Market-
check_circle
SLN / Market
SLN exceeded the US Market which returned 1.35% over the last twenty four hours.check_circle
SLN / Healthcare Sector
SLN exceeded the US Healthcare sector which returned 3.60% over the last twenty four hours.Silence Therapeutics plc (SLN) Statistics
Keep an eye on Silence Therapeutics plc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
help
What is the EPS of Silence Therapeutics plc (SLN) stock?
The Earnings Per Share (EPS) for Silence Therapeutics plc (SLN), calculated on a diluted basis, is -$1.7. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help
How has Silence Therapeutics plc (SLN) stock's performance compared to its sector and the market over the past year?
Over the past year, Silence Therapeutics plc (SLN) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 22.20%, Silence Therapeutics plc has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 37.38%, it has fallen short of the market average. This comparison highlights Silence Therapeutics plc's performance relative to both its sector and the overall market over the last year.
help
What is the PE ratio of Silence Therapeutics plc (SLN) stock?
The PE ratio for Silence Therapeutics plc (SLN) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help
What is the operating margin of Silence Therapeutics plc (SLN) stock?
The operating margin for Silence Therapeutics plc (SLN) is -1.97K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help
What is the EBITDA of Silence Therapeutics plc (SLN) stock?
The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Silence Therapeutics plc (SLN) is -$61.73M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help
How much debt does Silence Therapeutics plc (SLN) have?
Silence Therapeutics plc (SLN) has a total debt of $147.43K. The net debt, which accounts for cash and cash equivalents against the total debt, is -$61.81M.